Mr. Huitt Tracey reports

NERVGEN PHARMA GRANTS STOCK OPTIONS

Nervgen Pharma Corp. has granted 545,000 incentive stock options to employees and consultants of the company, including 100,000 to the company's officers and 15,000 to consultants providing investor relations services. The options are exercisable at a price of $2.74 per share. Fifteen thousand of the options are exercisable for a period of five years and vest equally every three months over a one-year period, and 530,000 of the options are exercisable for a period of 10 years and vest equally every six months over a two-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan.

About Nervgen Pharma Corp.

Nervgen is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead molecule, NVG-291, in a phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.